Pharmacological Inhibition Of Bruton's Tyrosine Kinase Attenuates Experimental Abdominal Aortic Aneurysms
This activity was presented at 2020 VRIC as part of Abstract Session 3: Aortopathies and Novel Vascular Devices.
This study demonstrated that BTK inhibitor ibrutinib, FDA-approved drug, attenuated the formation of, and further progression of established, experimental AAAs in two mechanistically distinct but complementary AAA model systems. Our results suggest that pharmacological inhibition of BTK may represent a novel translational strategy for AAA disease suppression.
Professional Practice Gap
Macrophages are critical for abdominal aortic aneurysm (AAA) pathogenesis. Bruton’s tyrosine kinase (BTK) contributes to macrophage-driven diseases s. It is not known whether BTK plays a role in AAA disease. Additionally, currently there is no approved drugs for treating aortic aneurysm disease.
To create a virtual environment for the exchange of basic and translational vascular science that stimulates thoughtful discussion and motivates participants to discover solutions to important problems affecting vascular patients.
The opinions or views expressed on the SVS OnDemand platform and the SVS Video Library are those of the faculty and do not necessarily reflect the opinions, recommendations, or endorsement of SVS. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product or device mentioned. Information presented, as well as publications, technologies, products and/or services discussed, are intended to inform the learner about the knowledge, techniques, and experiences of SVS faculty who are willing to share such information with colleagues. The SVS disclaims any and all liability for damages to any individual user for all claims which may result from the use of said information, publications, technologies, products and/or services and events.